Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$4.71 USD

4.71
956,036

-0.42 (-8.19%)

Updated Aug 13, 2024 04:00 PM ET

Pre-Market: $4.77 +0.06 (1.27%) 9:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Agenus (AGEN) Is a Great Choice for "Trend" Investors, Here's Why

Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates

The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.

Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Company News for May 19, 2021

Companies In The News Are: WMT, TWLO, WFC, BRK.B, BMY, AGEN

Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 12.90% and -46.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -7.69% and 5.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

Agenus (AGEN) in Focus: Stock Moves 7.6% Higher

Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.

What to Expect for Applied Therapeutics (APLT) Q2 Earnings

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?

On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.

Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

Agenus (AGEN) is a Great Momentum Stock: Should You Buy?

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Moving Average Crossover Alert: Agenus

Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

What Makes Agenus (AGEN) a Strong Momentum Stock: Buy Now?

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Is (AGEN) Outperforming Other Medical Stocks This Year?

Agenus' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Agenus.